Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Buske

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Hemasphere|August 18, 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 PandemicDipti Talaulikar, Ranjana H Advani, Andrew R Branagan, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Nature Medicine|August 30, 2011
Stem cell gene expression programs influence clinical outcome in human leukemiaKolja Eppert, Katsuto Takenaka, Eric R Lechman, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
Cell Reports|June 28, 2016
MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AMLNaidu M Vegi, Josef Klappacher, Franz Oswald, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Cancer Cell|November 14, 2006
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemiaAniruddha J Deshpande, Monica Cusan, Vijay P S Rawat, et al.
Leukemia|May 16, 2020
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibitionShiva Bamezai, Deniz Demir, Alex Jose Pulikkottil, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Hemasphere|August 18, 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 PandemicDipti Talaulikar, Ranjana H Advani, Andrew R Branagan, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Nature Medicine|August 30, 2011
Stem cell gene expression programs influence clinical outcome in human leukemiaKolja Eppert, Katsuto Takenaka, Eric R Lechman, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
Cell Reports|June 28, 2016
MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AMLNaidu M Vegi, Josef Klappacher, Franz Oswald, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Cancer Cell|November 14, 2006
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemiaAniruddha J Deshpande, Monica Cusan, Vijay P S Rawat, et al.
Leukemia|May 16, 2020
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibitionShiva Bamezai, Deniz Demir, Alex Jose Pulikkottil, et al.
Pageof 15